iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

India's Pharma exports grow by 103% in 2021-22 despite global trade disruptions

2 May 2022 , 04:08 PM

Indian pharma exports witnessed a growth of 103% since 2013-14, from Rs. 90, 415 Crores in 2013-14 to Rs. 1,83,422 Crores in 2021-22.  The exports achieved in 2021-22 is the Pharma Sector’ best export performance ever.  It is a remarkable growth with exports growing by almost USD 10 billion in 8 years.

Highlighting the achievement in a tweet, the Union Minister of Commerce and Industry, Consumer Affairs, Food and Public Distribution and Textiles, Shri Piyush Goyal said that Under the active leadership of Prime Minister, Shri Narendra Modi India has been serving as the 'pharmacy of the world'.

Building on the outstanding performance in the previous FY 2020-21, Indian pharma exports once again registered a healthy performance in 2021-22.  The pharma exports in 2021-22 sustained a positive growth despite the global trade disruptions and drop in demand for COVID related medicines. The trade balance continues to be in India’s favour, with a surplus of USD 15175.81 Million.

Indian pharma companies enabled by their price competitiveness and good quality, have made global mark, with 60 per cent of the world’s vaccines and 20% of generic medicines coming from India.

India ranks 3rd worldwide for production by volume and 14th by value. Behind India’s pharma success story is our world class manufacturing excellence, robust infrastructure, cost-competitiveness, trained human capital and innovation. The current market size of the Indian pharmaceutical industry is around USD 50 billion.

The share of pharmaceutical and drugs in our global exports is 5.92%. Formulations and biologicals continue to account for a major share of 73.31% in our total exports, followed by Bulk drugs and drug intermediates with exports of USD 4437.64 million. India’s top 5 pharma export destinations are USA, UK, South Africa, Russia and Nigeria.

It is also noteworthy that around 55 % of our pharma exports cater to highly regulated markets. Indian pharma companies have a substantial share in the prescription market in the US and EU.  The largest number of FDA approved plants outside the US is in India.

Even in the year, 2020-21, Indian drugs and pharmaceuticals had registered a sharp growth amid the COVID despair, achieving   an export of USD 24.4 Bn with a YoY growth of 18%. 

The extraordinary exports growth in 2020-21 was achieved braving the frequent lock downs, global supply chain disruptions and the depressed manufacturing sector. Indian pharma industry   played a pivotal role in fighting against the COVID pandemic and demonstrating to the world that we continue to be a reliable and dependent partner when it comes to dealing with a global health crisis.

Indian vaccine industry developed Covid vaccine with indigenous technology in collaboration with India’s research institution like ICMR and NIV with in shortest time on par with highly developed countries like America and EU. India provided 115million doses of vaccines to more than 97 countries.

As part of the trade agreements, India also signed cooperation agreement with UAE and  Australia which will give enhanced access to Indian pharma products to these markets.

Related Tags

  • covid-19
  • pharma industry
  • Pharma Sector
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.